Last week, the FDA cleared the use of a new-to-market Continuous Glucose Management device named “Stelo” by Dexcon. It is reportedly a dumbed-down version of their G7 device competing with the Libre 3 from Abbott that I currently use. It is to be sold OTC without requiring a prescription and lacks some of the bells and whistles of the G7 such as high and low alarms etc. I would guess that it will be priced at a lower point than their current device and diabetics, as well as the broader target market, will also tend to use it. We’ll see. Read about it at this link. Dexcon’s stock has gone up by 10% since the announcement.
BTW, “Stelo” doesn’t seem to translate to anything, but “Steelo” means “style” in Spanish.
Leave a Reply